201 related articles for article (PubMed ID: 28096506)
1. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer.
Chen X; Oppenheim JJ
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096506
[TBL] [Abstract][Full Text] [Related]
2. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
[TBL] [Abstract][Full Text] [Related]
3. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
[TBL] [Abstract][Full Text] [Related]
4. Targeted killing of TNFR2-expressing tumor cells and T
Torrey H; Khodadoust M; Tran L; Baum D; Defusco A; Kim YH; Faustman DL
Leukemia; 2019 May; 33(5):1206-1218. PubMed ID: 30356161
[TBL] [Abstract][Full Text] [Related]
5. Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4⁺ Foxp3⁺ regulatory T cells.
Hu Y; Xiao H; Shi T; Oppenheim JJ; Chen X
Immunology; 2014 Jun; 142(2):193-201. PubMed ID: 24383743
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
Zou H; Li R; Hu H; Hu Y; Chen X
Front Immunol; 2018; 9():594. PubMed ID: 29632537
[TBL] [Abstract][Full Text] [Related]
7. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
8. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract][Full Text] [Related]
9. TNFR2: A Novel Target for Cancer Immunotherapy.
Vanamee ÉS; Faustman DL
Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
[TBL] [Abstract][Full Text] [Related]
10. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
[TBL] [Abstract][Full Text] [Related]
12. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
14. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
[TBL] [Abstract][Full Text] [Related]
15. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
16. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
[TBL] [Abstract][Full Text] [Related]
18. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4
Islam MS; Yang Y; Chen X
Adv Exp Med Biol; 2021; 1278():257-272. PubMed ID: 33523452
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.
Chopra M; Riedel SS; Biehl M; Krieger S; von Krosigk V; Bäuerlein CA; Brede C; Jordan Garrote AL; Kraus S; Schäfer V; Ritz M; Mattenheimer K; Degla A; Mottok A; Einsele H; Wajant H; Beilhack A
Carcinogenesis; 2013 Jun; 34(6):1296-303. PubMed ID: 23385062
[TBL] [Abstract][Full Text] [Related]
20. Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4
He T; Zhao Y; Zhao P; Zhao L; Zakaria J; Wang K
Int Immunopharmacol; 2022 Jul; 108():108823. PubMed ID: 35623290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
